BEIJING, China, 21-23 September 2023 – The 2023 Academic Annual Meeting of the Chinese Society of Nuclear Medicine was successfully held in the ancient capital Xi’an, where experts and scholars in nuclear medicine and related fields, excellent companies and industry elites gathered together. As a leading company of innovative radiopharmaceuticals, Sinotau also participated in this event.
The conference was organized by the Chinese Society of Nuclear Medicine (CSNM). Prof. Sijin Li of the First Hospital of Shanxi Medical University, former chairman of the CSNM, Prof. Jing Wang of Xijing Hospital, current member of the CSNM, and Prof. Hongcheng Shi of Zhongshan Hospital of Fudan University, the incoming chairman of the CSNM.
▲Opening Ceremony Site
With the theme of “Focusing on Precision, Expanding Innovation”, this conference aims to discuss the latest progress and future development direction of nuclear medicine and molecular imaging, and inject new impetus for the development of nuclear medicine. There were 17 sessions with rich and novel contents, covering PET and tumor, neurology, cardiovascular, functional imaging, nuclide therapy, radiopharmaceuticals and other fields, with a total of nearly 200 papers exchanged, which comprehensively demonstrated the latest achievements in the development of China’s nuclear medicine, and aimed to provide a comprehensive and in-depth platform for participants to have in-depth academic exchanges and interactions.
In the form of depth involvement in this grand event, Sinotau participated in the form of new technology exchange and special exhibition. In the segment of new technology exchange, Dr. He Wei, Senior Medical Manager of Sinotau, shared the application of “Aβ-PET imaging agent Florbetaben F 18 injection in AD diagnosis”. This product was officially approved by the National Medical Products Administration (NMPA) this month, and is the first domestically approved Aβ-PET imaging agent for AD diagnosis.
▲Dr. He Wei delivered a speech at the conference
The exhibition section showcased the company’s major milestones and two listed products – Adenosine Injection（with Chinese trade name欧达乐®）and, Aβ-PET Imaging radiotracer florbetaben F-18 injection（with Chinese trade name欧韦宁®）. During the exhibition, colleagues from the nuclear medicine and related fields nationwide showed a keen interest in the Sinotau’s products and actively sought advice from the staff.
In recent years, the Party and the State have attached great importance to the development of nuclear medicine, and under the impetus of policy support and institutional guarantee, China’s nuclear medicine has ushered in the long-awaited spring, and the year of 2023 will be a year of vigorous development for China’s nuclear medicine. Centron believes that the development of nuclear medicine in China will continue to flourish under the strong support of the policy and the vigorous efforts of nuclear medicine practitioners; Sinotau, as a company ahead of the innovative radiopharmaceuticals in China, will always uphold the mission of “Invent radiopharmaceuticals for lives”, and will continue to contribute to the development of China’s nuclear medicine cause.
▌About Florbetaben F 18 Injection(with Chinese Trade Name 欧韦宁®)
On September 15, Sinotau’s radiopharmaceutical product florbetaben F 18 injection(with Chinese trade name 欧韦宁®) was officially approved by the National Drug Administration (NMPA). Florbetaben F 18 injection is a radiotracer used for PET scanning of the brain, which can be used for the diagnosis, differential diagnosis and therapeutic evaluation of AD by determining the level of β-amyloid plaque (commonly known as senile plaques) deposition in the brain. Florbetaben F 18 injection is the first Aβ-PET imaging agent approved for AD diagnosis in China, which can realize early, accurate and non-invasive AD diagnosis, and fills the market gap of Aβ-PET diagnostic imaging agent in AD field in China.
▌About Adenosine Injection (with Chinese Trade Name 欧达乐®)
Adenosine Injection is the preferred classical drug for drug loading, which was approved by the National Drug Administration (NMPA) for marketing authorization in January this year. It is the only loading drug in China that combines two indications: it is used for myocardial perfusion imaging and echocardiographic drug loading test to assist in the diagnosis of coronary artery disease, and it has provided a new choice of non-invasive myocardial ischemia screening for patients with coronary artery disease in China. Adenosine has high sensitivity and specificity, good safety, and both domestic and international guideline consensus recommend adenosine as the preferred loading drug.